Xenon to Report Q3 2024 Financial Results on November 12, 2024
VANCOUVER, British Columbia and BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its third quarter 2024 financial results after the close of U.S. financial markets on Tuesday, November 12, 2024.
Conference Call/Webcast Information:
| Date: | Tuesday, November 12, 2024 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Webcast: | |
| Dial-In: | (800) 715-9871 toll-free or (646) 307-1963 for international callers |
| Conference ID: | 7128308 |
A live webcast of the company presentation will be available on the “” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit .
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
